{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:24:34Z","timestamp":1776119074733,"version":"3.50.1"},"reference-count":29,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2013]]},"DOI":"10.1536\/ihj.54.98","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T05:40:39Z","timestamp":1365054039000},"page":"98-106","source":"Crossref","is-referenced-by-count":23,"title":["Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure"],"prefix":"10.1536","volume":"54","author":[{"given":"Mayuko","family":"Ishikawa","sequence":"first","affiliation":[{"name":"Department of Cardiology and Nephrology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Onoda","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Ishimitsu","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Dokkyo Medical University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-9.","DOI":"10.1161\/01.CIR.0000116764.53225.A9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-22. (Review)","DOI":"10.1681\/ASN.2008121226"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Sebe A, Leivonen SK, Fintha A, <I>et al<\/I>. Transforming growth factor-beta-induced alpha-smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38beta mitogen-activated protein kinase, extracellular signal-regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation. Nephrol Dial Transplant 2008; 23: 1537-45.","DOI":"10.1093\/ndt\/gfm789"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zeisberg M, Hanai J, Sugimoto H, <I>et al<\/I>. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-8.","DOI":"10.1038\/nm888"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Fr&oslash;kiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-63. (Review)","DOI":"10.1681\/ASN.V103647"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Morooka H, Iwanaga Y, Tamaki Y, <I>et al<\/I>. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail 2012; 5: 484-92.","DOI":"10.1161\/CIRCHEARTFAILURE.111.965392"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kobayashi N, Hara K, Tojo A, <I>et al<\/I>. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilonMAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-44.","DOI":"10.1161\/01.HYP.0000157408.43807.5a"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nishikimi T, Inaba-Iemura C, Ishimura K, <I>et al<\/I>. Natriuretic peptide\/natriuretic peptide receptor-A (NPR-A) system has inhibitory effects in renal fibrosis in mice. Regul Pept 2009; 154: 44-53.","DOI":"10.1016\/j.regpep.2009.02.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res 2010; 33: 965-73.","DOI":"10.1038\/hr.2010.112"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Koshikawa S, Nishikimi T, Inaba C, Akimoto K, Matsuoka H. Fasudil, a Rho-kinase inhibitor, reverses L-NAME exacerbated severe nephrosclerosis in spontaneously hypertensive rats. J Hypertens 2008; 26: 1837-48.","DOI":"10.1097\/HJH.0b013e328305086c"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012; 76: 137-44.","DOI":"10.1253\/circj.CJ-11-0689"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kobayashi N, Yoshida K, Nakano S, <I>et al<\/I>. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 2006; 47: 671-9.","DOI":"10.1161\/01.HYP.0000203148.42892.7a"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kobayashi N, Takeshima H, Fukushima H, <I>et al<\/I>. Cardioprotective effects of pitavastatin on cardiac performance and remodeling in failing rat hearts. Am J Hypertens 2009; 22: 176-82.","DOI":"10.1038\/ajh.2008.333"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-34. (Review)","DOI":"10.2337\/diabetes.54.6.1626"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nishiyama A, Kobori H, Konishi Y, <I>et al<\/I>. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2010; 332: 1072-80.","DOI":"10.1124\/jpet.109.158113"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ihara G, Kiyomoto H, Kobori H, <I>et al<\/I>. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens 2010; 28: 2289-98.","DOI":"10.1097\/HJH.0b013e32833dfcda"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755-63.","DOI":"10.1093\/ndt\/gfg277"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Okada T, Sakaguchi T, Hatamura I, <I>et al<\/I>. Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol 2009; 13: 438-46.","DOI":"10.1007\/s10157-009-0196-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chabrashvili T, Tojo A, Onozato ML, <I>et al<\/I>. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39: 269-74.","DOI":"10.1161\/hy0202.103264"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Onozato ML, Tojo A, Kobayashi N, Goto A, Matsuoka H, Fujita T. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 2007; 22: 1314-22.","DOI":"10.1093\/ndt\/gfl780"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Armstead WM. Vasopressin-induced protein kinase C-dependent superoxide generation contributes to ATP-sensitive potassium channel but not calcium-sensitive potassium channel function impairment after brain injury. Stroke 2001; 32: 1408-14.","DOI":"10.1161\/01.STR.32.6.1408"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Li L, Galligan JJ, Fink GD, Chen AF. Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension. Hypertension 2003; 41: 663-8.","DOI":"10.1161\/01.HYP.0000047875.43777.79"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Bauer J, Parekh N. Variations in cell signaling pathways for different vasoconstrictor agonists in renal circulation of the rat. Kidney Int 2003; 63: 2178-86.","DOI":"10.1046\/j.1523-1755.2003.00021.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shimogai M, Ogawa K, Tokinaga Y, Yamazaki A, Hatano Y. The cellular mechanisms underlying the inhibitory effects of isoflurane and sevoflurane on arginine vasopressin-induced vasoconstriction. J Anesth 2010; 24: 893-900.","DOI":"10.1007\/s00540-010-1033-z"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Song J, Martin DS. Rho kinase contributes to androgen amplification of renal vasoconstrictor responses in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 2006; 48: 103-9.","DOI":"10.1097\/01.fjc.0000245403.45406.d8"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Satoh S, Ikegaki I, Toshima Y, Watanabe A, Asano T, Shimokawa H. Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats. Life Sci 2002; 72: 103-12.","DOI":"10.1016\/S0024-3205(02)02178-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Nishikimi T, Akimoto K, Wang X, <I>et al<\/I>. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens 2004; 22: 1787-96.","DOI":"10.1097\/00004872-200409000-00024"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005; 16: 846-51.","DOI":"10.1681\/ASN.2004121090"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP. Tolvaptan inhibits ERK-dependent cell proliferation, Cl<SUP>&minus;<\/SUP> secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 2011; 301: F1005-13.","DOI":"10.1152\/ajprenal.00243.2011"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/54\/2\/54_98\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T01:33:02Z","timestamp":1644715982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/54\/2\/54_98\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.54.98","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}